In Q1 FY2026 (ended March 31, 2026), Anteris Technologies Global Corp. reported revenue of $494,000, down 11.2% year-over-year. Net loss widened to $23.0 million, and operating loss was $24.0 million. Diluted EPS improved to -$0.28 from -$0.61 a year ago. The company held $31.7 million in cash and $278.4 million in equity, with no long-term debt.
•Revenue fell 11.2% YoY to $494,000.
•Net loss increased 5.3% to $23.0 million.
•Diluted EPS improved 54.1% to -$0.28.
•Cash and equivalents stood at $31.7 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Anteris Technologies Global Corp., a structural heart company develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
It also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings
Including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
What does Anteris Technologies Global Corp. (AVR) do?
Anteris Technologies Global Corp., trading under the ticker AVR, is a structural heart company that develops and commercializes minimally invasive medical devices to treat heart valve diseases. Its primary product is the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve designed to mimic the performance of a healthy human aortic valve for the treatment of severe aortic stenosis. The company also offers the ADAPT anti-calcification tissue, a preparation that transforms xenograft tissue into durable bioscaffolds used for surgical repair in settings like aortic valve replacement. Additionally, it provides the ComASUR delivery system, a physician-developed balloon expandable delivery system with a reinforced steerable catheter that allows precise deflection through the heart anatomy to avoid damage to the aorta.
Where is Anteris Technologies Global Corp. (AVR) listed and in which currency?
Anteris Technologies Global Corp. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol AVR. The company trades in US dollars (USD), reflecting its listing on a US-based exchange. Although its headquarters are in Toowong, Australia, the company is classified under the US region for listing purposes, indicating its primary market exposure is in the United States. Investors can buy and sell AVR shares on NasdaqGM using USD, making it accessible to international investors through US brokerage accounts.
What sector and industry does Anteris Technologies Global Corp. (AVR) belong to?
Anteris Technologies Global Corp. operates in the Healthcare sector, specifically within the Medical Instruments & Supplies industry. This classification means the company is involved in the development, manufacturing, and commercialization of medical devices and supplies used in healthcare settings. In plain language, Anteris focuses on creating advanced tools and technologies for medical procedures, particularly in the field of structural heart disease. Its products, such as the DurAVR heart valve system and the ADAPT anti-calcification tissue, are designed for minimally invasive cardiac surgeries, placing it at the intersection of medical device innovation and cardiovascular care.
Where is Anteris Technologies Global Corp. (AVR) headquartered and what markets does it serve?
Anteris Technologies Global Corp. is headquartered in Toowong, Australia, a suburb of Brisbane. Despite its Australian base, the company serves global markets, with a particular focus on the United States, as indicated by its listing on the NasdaqGM and its use of USD. The company's products, such as the DurAVR transcatheter heart valve system, are designed for the treatment of severe aortic stenosis, a condition that affects patients worldwide. While the headquarters are in Australia, Anteris likely targets major healthcare markets including North America, Europe, and Asia-Pacific, leveraging its ADAPT anti-calcification technology and delivery systems to address the needs of cardiac surgeons and interventional cardiologists globally.
What are the main products and technologies of Anteris Technologies Global Corp. (AVR)?
Anteris Technologies Global Corp. has a portfolio centered on three key offerings. First, the DurAVR transcatheter heart valve system is a novel aortic valve shaped to mimic the performance of a healthy human valve, used to treat severe aortic stenosis via a minimally invasive procedure. Second, the ADAPT anti-calcification tissue is a proprietary preparation that transforms animal-derived xenograft tissue into durable bioscaffolds, which can be used in surgical repairs such as aortic valve replacement. Third, the ComASUR delivery system is a physician-developed balloon expandable catheter with a reinforced steerable design, enabling precise navigation through the heart anatomy while minimizing risk of aortic damage. Together, these technologies aim to improve outcomes for patients with structural heart disease.